Wheat-specific immunoglobulin E (Wheat sIgE)

Wheat-specific immunoglobulin E (IgE) refers to a specialized class of patient-derived antibodies that recognize and bind to specific proteins found in wheat, such as gliadins, glutenins, and alpha-amylase inhibitors (Matsuo et al., 2004, FEBS Lett). These antibodies are the primary mediators of Type I hypersensitivity reactions, including food-induced wheat allergy and wheat-dependent exercise-induced anaphylaxis (WDEIA) (Sampson, 2004, J Allergy Clin Immunol). In sensitized individuals, these IgE molecules are found bound to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to wheat allergens, the cross-linking of these surface-bound IgE antibodies triggers the rapid release of inflammatory mediators like histamine and leukotrienes, leading to clinical symptoms ranging from urticaria to life-threatening anaphylaxis. From a therapeutic perspective, IgE is a validated target for monoclonal antibodies like Omalizumab, which sequester free IgE and downregulate receptor expression on effector cells to mitigate allergic cascades (Xolair Prescribing Information). Monitoring the levels of these antibodies serves as a critical diagnostic tool and biomarker for assessing the severity and risk of allergic reactions in patients.

Other names

Wheat-specific IgEAnti-wheat IgE antibodiesWheat allergen-specific IgEPatient-derived anti-wheat IgE

Neutralization of circulating free IgE by binding to the Cε3 domain, which prevents the interaction of IgE with high-affinity (FcεRI) and low-affinity (FcεRII/CD23) receptors on effector cells (Xolair Prescribing Information, Genentech/Novartis).